- Ashok Leyland reported vehicle sales of 17,213 units in January 2025.
- Sales saw an increase of 8% compared to the same period last year, which recorded 15,939 units.
- Local sales amounted to 15,327 units, marking a 2.9% increase year-over-year.
- Market analysts provided 34 buy recommendations for Ashok Leyland.
- There are also 5 hold recommendations from analysts.
- Analysts issued 6 sell recommendations, reflecting varied perspectives on the company’s stock.
“`
A look at Ashok Leyland Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 5 | |
| Growth | 5 | |
| Resilience | 2 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Based on Smartkarma Smart Scores, Ashok Leyland has a strong long-term outlook. With high scores in Dividend and Growth, the company is positioned well to deliver solid returns to investors. Its focus on shareholder returns through dividends and promising growth prospects indicate a positive future trajectory.
However, the company faces challenges in the areas of Value and Resilience, which could impact its overall performance. The moderate score in Momentum suggests the need for Ashok Leyland to enhance its market traction. Overall, given its core strengths in Dividend and Growth, Ashok Leyland‘s strategic position in manufacturing commercial vehicles and diverse product offerings provide a foundation for future success.
**Summary:**
Ashok Leyland Limited manufactures a range of commercial vehicles, industrial & marine engines, and spare parts, catering to domestic and international markets. The company’s product portfolio includes buses, tractors, haulage trucks, fire engines, and defense sector vehicles, showcasing its diversified business operations.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
